Bluebird bio opens lentiviral vector manufacturing facility
bluebird bio, Inc.
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor - bluebird bio,
bluebird bio reports new data for Lenti-D gene therapy
bluebird bio - YouTube
Bluebird reveals positive gene therapy data - Biotechnology
Bluebird Bio: On The Cusp Of A Gene Therapy Revolution
Why bluebird bio Inc Presented a Lower Price Today | The Motley Fool
FDA panel backs bluebird's CALD gene therapy, despite safety worries -
bluebird bio: Market Fails To React To Impressive Data On Lenti-D Gene Therapy For CALD (NASDAQ:BLUE) | Seeking Alpha
Bluebird to Request Lenti-D, Cell Therapy for CALD Be Approved in EU
Bluebird Bio CEO Charts Comeback Course for the Lentiviral Vector Company | GEN Biotechnology
Positive outcomes for Lenti-D trial, bluebird chasing regulatory approvals
EU go-ahead for bluebird bio gene therapy for CALD
bluebird bio: Market Fails To React To Impressive Data On Lenti-D Gene Therapy For CALD (NASDAQ:BLUE) | Seeking Alpha
bluebird bio: Market Fails To React To Impressive Data On Lenti-D Gene Therapy For CALD (NASDAQ:BLUE) | Seeking Alpha
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor | Business Wire
Bluebird Seeks EU Fast-Track Review For Lenti-D Gene Therapy :: Pink Sheet
PharmaShots | Incisive News in 3 Shots
bluebird bio (BLUE) Investor Presentation - Slideshow (NASDAQ:BLUE) | Seeking Alpha
Bluebird bio Reports US FDA Acceptance of BLA for Priority Review of Lenti-D (elivaldogene autotemcel)
Bluebird Bio Inc. | BioWorld
Gene Therapy for ALD - Adrenoleukodystrophy.info
Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold - Benzinga
With the pricing situation 'untenable' in Europe, Bluebird will wind down its operations in the 'broken' market | Fierce Pharma
SEC Filing - bluebird bio, Inc.
